世界の急性リンパ性/リンパ芽球性白血病治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-2104Z00332 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、急性リンパ性/リンパ芽球性白血病治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性リンパ性/リンパ芽球性白血病治療薬の種類別市場規模（化学療法、標的療法、放射線療法、幹細胞移植）、用途別市場規模（病院、薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・急性リンパ性/リンパ芽球性白血病治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Valeo、Continental、Magna International、Hitachi Automotive、Fujitsu、Ficosa ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：化学療法、標的療法、放射線療法、幹細胞移植 ・用途別分析2016年-2026年：病院、薬局 ・急性リンパ性/リンパ芽球性白血病治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・急性リンパ性/リンパ芽球性白血病治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・急性リンパ性/リンパ芽球性白血病治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・急性リンパ性/リンパ芽球性白血病治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・急性リンパ性/リンパ芽球性白血病治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Chemotherapy
Targeted Therapy
Radiation Therapy
Stem cell Transplantation

Market segment by Application, can be divided into
Hospital
Pharmacy

Market segment by players, this report covers
Erytech Pharma
Spectrum Pharmaceuticals
Pfizer
Sigma-Tau
Takeda
Genzyme Corporatio
GSK
Amgen
EUSA Pharma
ARIAD Pharmaceuticals
Talon Therapeutics
Enzon, Inc.
Nova Laboratories
Bristol-Myers Squibb
Silvergate Pharmaceuticals

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics
1.2 Classification of Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics by Type
1.2.1 Overview: Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Type in 2020
1.2.3 Chemotherapy
1.2.4 Targeted Therapy
1.2.5 Radiation Therapy
1.2.6 Stem cell Transplantation
1.3 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market by Application
1.3.1 Overview: Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size & Forecast
1.5 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast by Region
1.5.1 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Drivers
1.6.2 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Restraints
1.6.3 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Trends Analysis
2 Company Profiles
2.1 Erytech Pharma
2.1.1 Erytech Pharma Details
2.1.2 Erytech Pharma Major Business
2.1.3 Erytech Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.1.4 Erytech Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Erytech Pharma Recent Developments and Future Plans
2.2 Spectrum Pharmaceuticals
2.2.1 Spectrum Pharmaceuticals Details
2.2.2 Spectrum Pharmaceuticals Major Business
2.2.3 Spectrum Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.2.4 Spectrum Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Spectrum Pharmaceuticals Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.3.4 Pfizer Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Sigma-Tau
2.4.1 Sigma-Tau Details
2.4.2 Sigma-Tau Major Business
2.4.3 Sigma-Tau Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.4.4 Sigma-Tau Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Sigma-Tau Recent Developments and Future Plans
2.5 Takeda
2.5.1 Takeda Details
2.5.2 Takeda Major Business
2.5.3 Takeda Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.5.4 Takeda Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Takeda Recent Developments and Future Plans
2.6 Genzyme Corporatio
2.6.1 Genzyme Corporatio Details
2.6.2 Genzyme Corporatio Major Business
2.6.3 Genzyme Corporatio Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.6.4 Genzyme Corporatio Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Genzyme Corporatio Recent Developments and Future Plans
2.7 GSK
2.7.1 GSK Details
2.7.2 GSK Major Business
2.7.3 GSK Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.7.4 GSK Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 GSK Recent Developments and Future Plans
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business
2.8.3 Amgen Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.8.4 Amgen Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Amgen Recent Developments and Future Plans
2.9 EUSA Pharma
2.9.1 EUSA Pharma Details
2.9.2 EUSA Pharma Major Business
2.9.3 EUSA Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.9.4 EUSA Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 EUSA Pharma Recent Developments and Future Plans
2.10 ARIAD Pharmaceuticals
2.10.1 ARIAD Pharmaceuticals Details
2.10.2 ARIAD Pharmaceuticals Major Business
2.10.3 ARIAD Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.10.4 ARIAD Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 ARIAD Pharmaceuticals Recent Developments and Future Plans
2.11 Talon Therapeutics
2.11.1 Talon Therapeutics Details
2.11.2 Talon Therapeutics Major Business
2.11.3 Talon Therapeutics Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.11.4 Talon Therapeutics Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Talon Therapeutics Recent Developments and Future Plans
2.12 Enzon, Inc.
2.12.1 Enzon, Inc. Details
2.12.2 Enzon, Inc. Major Business
2.12.3 Enzon, Inc. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.12.4 Enzon, Inc. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Enzon, Inc. Recent Developments and Future Plans
2.13 Nova Laboratories
2.13.1 Nova Laboratories Details
2.13.2 Nova Laboratories Major Business
2.13.3 Nova Laboratories Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.13.4 Nova Laboratories Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Nova Laboratories Recent Developments and Future Plans
2.14 Bristol-Myers Squibb
2.14.1 Bristol-Myers Squibb Details
2.14.2 Bristol-Myers Squibb Major Business
2.14.3 Bristol-Myers Squibb Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.14.4 Bristol-Myers Squibb Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.15 Silvergate Pharmaceuticals
2.15.1 Silvergate Pharmaceuticals Details
2.15.2 Silvergate Pharmaceuticals Major Business
2.15.3 Silvergate Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
2.15.4 Silvergate Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Silvergate Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Players Market Share
3.2.2 Top 10 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2026)
6.2 North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2026)
6.3 North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Country
6.3.1 North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2026)
7.2 Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2026)
7.3 Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Country
7.3.1 Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Region (2016-2026)
8.3.2 China Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2026)
9.2 South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2026)
9.3 South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Country
9.3.1 South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Erytech Pharma Corporate Information, Head Office, and Major Competitors
Table 7. Erytech Pharma Major Business
Table 8. Erytech Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 9. Erytech Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Spectrum Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Spectrum Pharmaceuticals Major Business
Table 12. Spectrum Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 13. Spectrum Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Pfizer Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Major Business
Table 16. Pfizer Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 17. Pfizer Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Sigma-Tau Corporate Information, Head Office, and Major Competitors
Table 19. Sigma-Tau Major Business
Table 20. Sigma-Tau Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 21. Sigma-Tau Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Takeda Corporate Information, Head Office, and Major Competitors
Table 23. Takeda Major Business
Table 24. Takeda Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 25. Takeda Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Genzyme Corporatio Corporate Information, Head Office, and Major Competitors
Table 27. Genzyme Corporatio Major Business
Table 28. Genzyme Corporatio Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 29. Genzyme Corporatio Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. GSK Corporate Information, Head Office, and Major Competitors
Table 31. GSK Major Business
Table 32. GSK Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 33. GSK Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Amgen Corporate Information, Head Office, and Major Competitors
Table 35. Amgen Major Business
Table 36. Amgen Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 37. Amgen Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. EUSA Pharma Corporate Information, Head Office, and Major Competitors
Table 39. EUSA Pharma Major Business
Table 40. EUSA Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 41. EUSA Pharma Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. ARIAD Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 43. ARIAD Pharmaceuticals Major Business
Table 44. ARIAD Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 45. ARIAD Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Talon Therapeutics Corporate Information, Head Office, and Major Competitors
Table 47. Talon Therapeutics Major Business
Table 48. Talon Therapeutics Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 49. Talon Therapeutics Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Enzon, Inc. Corporate Information, Head Office, and Major Competitors
Table 51. Enzon, Inc. Major Business
Table 52. Enzon, Inc. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 53. Enzon, Inc. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Nova Laboratories Corporate Information, Head Office, and Major Competitors
Table 55. Nova Laboratories Major Business
Table 56. Nova Laboratories Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 57. Nova Laboratories Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 59. Bristol-Myers Squibb Major Business
Table 60. Bristol-Myers Squibb Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 61. Bristol-Myers Squibb Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Silvergate Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 63. Silvergate Pharmaceuticals Major Business
Table 64. Silvergate Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Product and Solutions
Table 65. Silvergate Pharmaceuticals Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 67. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Share by Players (2019-2021)
Table 68. Breakdown of Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 69. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Players Head Office, Products and Services Provided
Table 70. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Mergers & Acquisitions in the Past Five Years
Table 71. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics New Entrants and Expansion Plans
Table 72. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 73. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Share by Type (2016-2021)
Table 74. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Forecast by Type (2021-2026)
Table 75. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2021)
Table 76. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Forecast by Application (2021-2026)
Table 77. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 78. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 79. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 80. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 81. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 82. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 83. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 84. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 85. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 86. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 87. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 88. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 89. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 90. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 91. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 92. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 93. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 94. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 95. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 96. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 97. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 98. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 99. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 100. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 101. Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 102. Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 103. Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 104. Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 105. Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 106. Middle East & Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Picture
Figure 2. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Type in 2020
Figure 3. Chemotherapy
Figure 4. Targeted Therapy
Figure 5. Radiation Therapy
Figure 6. Stem cell Transplantation
Figure 7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Application in 2020
Figure 8. Hospital Picture
Figure 9. Pharmacy Picture
Figure 10. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Drivers
Figure 19. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Restraints
Figure 20. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Trends
Figure 21. Erytech Pharma Recent Developments and Future Plans
Figure 22. Spectrum Pharmaceuticals Recent Developments and Future Plans
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Sigma-Tau Recent Developments and Future Plans
Figure 25. Takeda Recent Developments and Future Plans
Figure 26. Genzyme Corporatio Recent Developments and Future Plans
Figure 27. GSK Recent Developments and Future Plans
Figure 28. Amgen Recent Developments and Future Plans
Figure 29. EUSA Pharma Recent Developments and Future Plans
Figure 30. ARIAD Pharmaceuticals Recent Developments and Future Plans
Figure 31. Talon Therapeutics Recent Developments and Future Plans
Figure 32. Enzon, Inc. Recent Developments and Future Plans
Figure 33. Nova Laboratories Recent Developments and Future Plans
Figure 34. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 35. Silvergate Pharmaceuticals Recent Developments and Future Plans
Figure 37. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Share by Players in 2020
Figure 38. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 39. Global Top 3 Players Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share in 2020
Figure 40. Global Top 10 Players Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share in 2020
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 42. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Share by Type in 2020
Figure 43. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Share Forecast by Type (2021-2026)
Figure 44. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Share by Application in 2020
Figure 45. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Share Forecast by Application (2021-2026)
Figure 46. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 47. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 48. North America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 49. United States Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Canada Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Mexico Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 53. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 54. Europe Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 55. Germany Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. France Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. United Kingdom Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Russia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Italy Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 61. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 63. China Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Japan Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South Korea Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. India Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Southeast Asia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Australia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 70. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 71. South America Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 72. Brazil Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 75. Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 76. Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. UAE Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source

---